Simoa’s Multiplexing Capabilities Featured in the Journal of Immunological Methods Highlights the Technology’s Remarkably Sensitive and Precise Single Molecule Measurement
LEXINGTON, MA – May 20, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that a study, prominently featuring Simoa’s multiplexing capabilities, has been published in The Journal of Immunological Methods. The study highlights Simoa’s remarkable multiplexing capabilities and how they will be of tremendous value in helping researchers benefit from Simoa’s ultra-sensitivity while measuring multiple analytes in a single sample.
In the study, Rivnak et. al. report developing a 6-plex cytokine Simoa assay for IL-6, TNF-α, GM-CSF, IL-10, IL-1β, and IL-1α , and obtaining limits of detection for all six analytes ranging from .01-.03 pg/ml, or several hundred times more sensitive than even the best singleplex assays available for those markers today. The assay showed exquisite precision with average CVs of 4.2 percent, and the values obtained for each of the analytes correlated closely with measurements taken of each analyte independently. The assay was used to measure samples of diabetic patients as well as those suffering from Crohn’s disease and was able to quantify the effect that candidate anti-cytokine drugs have on the systemic concentration of drug targets and related proteins.
“I would like to recognize our incredible team of scientists and engineers at Quanterix for this game changing achievement,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “Many of our customers have recognized our unparalleled capability to deliver a fully automated, bleed-to-read, ultra sensitive and precise single molecule protein detection technology and have indicated if we could deliver this same capability in a multiplex assay, it would be revolutionary for precision medicine, discovery and diagnostics. This study clearly demonstrates that Simoa can do just that.”
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.
Nikki Festa & Caitlyn Keating
Share this page